A federal judge has paused the new 340B rebate model set to begin Jan. 1, giving hospitals breathing room but leaving financial and compliance uncertainty for CFOs.
A U.S. District Court judge granted a preliminary injunction blocking the Health Resources and Services Administration’s (HRSA) 340B rebate pilot program from going into effect. The pilot would have shifted drug pricing from upfront discounts to post-sale rebates, a change hospital groups argued would strain cash flow and operations. HHS is appealing the ruling, keeping CFOs on alert.
Check out this infographic for three keytakeaways for CFOs.
Marie DeFreitas is the CFO editor for HealthLeaders.